Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol

Peter J. Blankestijn(Utrecht University), Michiel L. Bots(Utrecht University), Krister Cromm(Humboldt-Universität zu Berlin), Matthias Rose(Humboldt-Universität zu Berlin), Robin W.M. Vernooij(Utrecht University), Mark Woodward(UNSW Sydney), Cláudia Barth(OsloMet – Oslo Metropolitan University), Jörgen Hegbrant(Lund University), Bernard Canaud(Université de Montpellier), G. Ardine de Wit(Utrecht University), Kathrin I. Fischer(Boehringer Ingelheim (Germany)), Giovanni FM Strippoli(The University of Sydney), Kit C. B. Roes(Radboud University Nijmegen), Andrew Davenport(The Royal Free Hospital), Diederick E. Grobbee(University Medical Center Utrecht)
BMJ Open
February 1, 2020
10.1136/bmjopen-2019-033228
Cited by 67

Related Papers

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
|The Lancet|2010|4.2k
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
|The Lancet|2021|3.8k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k